245 related articles for article (PubMed ID: 34754233)
21. Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
Zhang K; Ma X; Gao H; Wang H; Qin H; Yang S; Liu X
Cancer Manag Res; 2020; 12():3409-3417. PubMed ID: 32494205
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and Tolerability of Anlotinib Plus PD-1 Inhibitors for Patients with Previously Treated Metastatic Soft-Tissue Sarcoma.
Sun X; Xu J; Xie L; Guo W
Int J Gen Med; 2022; 15():7581-7591. PubMed ID: 36196372
[TBL] [Abstract][Full Text] [Related]
23. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients.
Chen Y; Jiang N; Liang X; Chen N; Chen Y; Zhang C; Shi J; Guo R
Oncol Lett; 2023 Aug; 26(2):323. PubMed ID: 37415629
[TBL] [Abstract][Full Text] [Related]
24. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
Front Oncol; 2022; 12():939343. PubMed ID: 35965587
[TBL] [Abstract][Full Text] [Related]
25. The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer.
Zhai C; Zhang X; Ren L; You L; Pan Q; Pan H; Han W
Front Oncol; 2020; 10():619010. PubMed ID: 33680942
[TBL] [Abstract][Full Text] [Related]
26. Etoposide soft capsule combined with anlotinib in the third-line treatment of advanced non-small cell lung cancer: a retrospective cohort study.
Dai YJ; Qiu YR; Lin JG; Dai YB; Su YX; Yamada T; Uematsu S; Xu TW
J Thorac Dis; 2023 Oct; 15(10):5680-5688. PubMed ID: 37969289
[TBL] [Abstract][Full Text] [Related]
27. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
[TBL] [Abstract][Full Text] [Related]
28. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
Front Oncol; 2022; 12():885350. PubMed ID: 35860585
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Drug-Eluting Bead Bronchial Arterial Chemoembolization Plus Anlotinib in Patients With Advanced Non-small-Cell Lung Cancer.
Liu J; Zhang W; Ren J; Li Z; Lu H; Sun Z; Han X
Front Cell Dev Biol; 2021; 9():768943. PubMed ID: 34778275
[No Abstract] [Full Text] [Related]
30. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
[TBL] [Abstract][Full Text] [Related]
31. The real-world efficacy and safety of anlotinib in advanced non-small cell lung cancer.
Wang F; Jin F; Cheng B; Zhang Y; Zhou Q; Wang S
J Cancer Res Clin Oncol; 2022 Jul; 148(7):1721-1735. PubMed ID: 34357411
[TBL] [Abstract][Full Text] [Related]
32. Feasibility and Tolerability of Anlotinib Plus PD-1 Blockades for Patients with Treatment-Refractory Metastatic Colorectal Cancer: A Retrospective Exploratory Study.
Bai H; Wang WH; Zhou FF; Yang D; Li RJ
Cancer Manag Res; 2024; 16():73-86. PubMed ID: 38318097
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure-A Retrospective Study.
Wang P; Fang X; Yin T; Tian H; Yu J; Teng F
Front Oncol; 2021; 11():628124. PubMed ID: 33791214
[TBL] [Abstract][Full Text] [Related]
34. A Real-World Study of Optimal Treatment with Anlotinib First-Line Therapy in Advanced Hepatocellular Carcinoma.
Li Q; Su T; Zhang X; Pan Y; Ma S; Zhang L; Zhang X; Gao X
Cancer Manag Res; 2022; 14():3037-3046. PubMed ID: 36275784
[TBL] [Abstract][Full Text] [Related]
35. Salvage treatment with anlotinib for advanced non-small cell lung cancer.
Wu D; Nie J; Dai L; Hu W; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Thorac Cancer; 2019 Jul; 10(7):1590-1596. PubMed ID: 31183998
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study.
Yuan J; Cheng F; Xiao G; Wang X; Fan H
Front Oncol; 2022; 12():917089. PubMed ID: 35795060
[TBL] [Abstract][Full Text] [Related]
37. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
[TBL] [Abstract][Full Text] [Related]
38. Anlotinib Combined with S-1 in Third- or Later-Line Stage IV Non-Small Cell Lung Cancer Treatment: A Phase II Clinical Trial.
Xiang M; Yang X; Ren S; Du H; Geng L; Yuan L; Wen Y; Lin B; Li J; Zhang Y; Feng G; Du X
Oncologist; 2021 Dec; 26(12):e2130-e2135. PubMed ID: 34423518
[TBL] [Abstract][Full Text] [Related]
39. A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer.
Wang HY; Chu JF; Zhao Y; Tang H; Wang LL; Zhou MQ; Yan Z; Liu YY; Yao ZH
Cancer Manag Res; 2020; 12():3827-3834. PubMed ID: 32547218
[TBL] [Abstract][Full Text] [Related]
40. Retrospective Review of Efficacy and Safety of Anlotinib in Advanced Leiomyosarcoma: A Real-World Study.
Zou H; Xia L; Jin G; Wu H; Qian W; Jia D; Xu H; Li T
Cancer Manag Res; 2022; 14():1703-1711. PubMed ID: 35585940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
